Vimarsana
Biggest News Aggregation in the World

Marc Pfeffer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Marc Pfeffer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Marc Pfeffer Today - Breaking & Trending Today

Slain Temple University police officer's family sues suspect, parents - Vimarsana News

Slain Temple University police officer's family sues suspect, parents

Calling Christopher Fitzgerald’s death “a horrific and tragic act of barbarism,” the lawsuit seeks damages against Miles Pfeffer for wrongful death and assault.

Dr. Marc Pfeffer joins the K+N Management Board - Vimarsana News

Dr. Marc Pfeffer joins the K+N Management Board

FreightWeek - Insights on sustainable business practices for the global logistics industry

Marc Pfeffer to join management board of Kuehne+Nagel - Vimarsana News

Marc Pfeffer to join management board of Kuehne+Nagel

Marc Pfeffer has been heading legal dept since 2014 with responsibilities including trade control & data protection

Brigham-led clinical trials take center stage at the American College of Cardiology - Vimarsana News

Brigham-led clinical trials take center stage at the American College of Cardiology

Top experts from Brigham and Women's Hospital presented outcomes from some of the most-anticipated clinical trials in cardiology at the virtual American College of Cardiology's 70th Annual Scientific Session. In four Late-Breaking Clinical Trial presentations, Brigham cardiologists shared their latest findings on strategies to prevent future cardiovascular events in at-risk patient populations, results of a randomized clinical trial of a statin drug among patients critically ill with COVID-19, and more.

Sacubitril/Valsartan Does Not Outperform ACE Inhibitor in Preventing Heart Failure After Heart Attack - Vimarsana News

Sacubitril/Valsartan Does Not Outperform ACE Inhibitor in Preventing Heart Failure After Heart Attack

Trial finds favorable safety but no significant reduction in subsequent heart failure or death